Peter Attia· MD
i think still the data has not seen the light of day yet
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
i think still the data has not seen the light of day yet
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
but it is possible at least for that molecule to use it clinically at dose is where there's some reason to believe there might be some efficacy before letting David chime in can I just ask a question to clarify that um in the rtb 101 trial um did they didn't they combine it with another agent they did with ever alignment so they had two arms one was the combination and one was rtb 101 alone yeah yeah yeah no so so um I think Matt look I'm sorry I meant to my my shaking was that I was agreeing with you and and I was I actually was that that's study that that that manic did after I was confounded by that study and perplexed because this RTP which they 10 one they renamed I